Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy
Authors:
Open Access
- 1 October 2019
- journal article
- research article
- Published by Elsevier in Cell Reports
- Vol. 29 (2) , 249-257.e8
Abstract
No abstract availableKeywords
Funding Information
- Canadian HIV Trials Network, Canadian Institutes of Health Research
- U.S. Department of War
- Terry Fox Research Institute
- Canada Research Chairs
This publication has 61 references indexed in Scilit:
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2Proceedings of the National Academy of Sciences, 2013
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis toolBMC Bioinformatics, 2013
- Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancerGenome Research, 2011
- Primary trastuzumab resistance: new tricks for an old drugAnnals of the New York Academy of Sciences, 2010
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Polycomb complexes act redundantly to repress genomic repeats and genesGenes & Development, 2010
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinomaBritish Journal of Cancer, 2009
- EZH1 Mediates Methylation on Histone H3 Lysine 27 and Complements EZH2 in Maintaining Stem Cell Identity and Executing PluripotencyMolecular Cell, 2008
- ShcA signalling is essential for tumour progression in mouse models of human breast cancerThe EMBO Journal, 2008